Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Phase 2 Active not recruiting 183 enrolled Gannex Pharma Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).

Timeline

Start: 2022-09-30
Primary completion: 2025-05-10
Completion: 2025-06-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASC41	Unknown	2 mg	Oral
Subject	ASC41	Unknown	4 mg	Oral

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Summary

Timeline

Drugs

Indications